TLGS services & expertise · Curated intelligence
Healthcare, Pharma & Life Sciences is a critical pillar of India's economy and social infrastructure, overseen by the Ministry of Health & Family Welfare, Ministry of Chemicals & Fertilizers (Pharma division), and NITI Aayog. India is the world's largest supplier of generic medicines, supplying over 20% of global generic drug exports, while domestic health infrastructure is being scaled through Ayushman Bharat and the National Health Mission. Policy direction focuses on universal health coverage, PLI-driven pharma manufacturing, and positioning India as a global hub for medical devices and biologics.
Bharat Pulse · Enterprise intelligence · 17 September 2026
Policy developments translated into commercial implications, decisions and practical next steps.
For large enterprises, rate changes, exemptions and process reform become material through credit treatment, contracts, master data and the quality of the compliance record.
Effective framework · further process-reform watch
Read the brief & business implications →Reviewed 17 September 2026Bharat Pulse · TLGS Research · 2026-09-15
Official-source facts and TLGS perspectives, separated by status. An announced project is not an open bid; consultancy fees are distinct from the value of the underlying project.
Prepared research edition. Advertised notices require current issuer, corrigendum and award-status checks. This is not an exhaustive live procurement feed or a statement that TLGS is retained on these projects.
No researched record matches this selection. No substitute opportunity has been inferred.
Bharat Pulse · Healthcare regulatory insights
Dated regulatory notes with official references and a separately identified TLGS perspective.
A Maharashtra FDA order brings prescription access and patient choice into the operating controls of hospital-linked pharmacy services.
Official order · reviewed 13 September 2026
Read the sourced insight →Current Maharashtra FDA portal guidance makes application-channel verification an important first step for new manufacturing and sales users.
Official portal guidance · reviewed 13 September 2026
Read the sourced insight →A central-government reply explains the public drug-alert process. For retail and e-pharmacy networks, the operating question is how an alert becomes a traceable, location-specific response.
Official parliamentary reply · reviewed 13 September 2026
Read the sourced insight →These are independent TLGS sector notes, not Tata 1mg statements or findings about a client. Review dates are not announcement dates.
Engage TLGS
Connect the right expertise with your next decision.
